Definium Therapeutics (DFTX) Other Non-Current Liabilities (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Other Non-Current Liabilities data on file, last reported at $559000.0 in Q1 2026.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $559000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $559000.0 (changed N/A YoY) and the FY2025 annual result came in at $496000.0, changed N/A from the prior year.
• Other Non-Current Liabilities improved to $559000.0 in Q1 2026 per DFTX's latest filing, from $496000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $1.9 million in Q2 2022 and bottomed at $15000.0 in Q1 2024.
• The 5-year median for Other Non-Current Liabilities is $551000.0 (2025), against an average of $746333.3.
• The widest annual swing landed in 2022, when Other Non-Current Liabilities tumbled 38.65%; it then plunged 98.62% in 2024.
• Tracing DFTX's Other Non-Current Liabilities over 5 years: stood at $1.2 million in 2022, then slumped by 97.3% to $32000.0 in 2023, then plunged by 53.12% to $15000.0 in 2024, then surged by 3206.67% to $496000.0 in 2025, then rose by 12.7% to $559000.0 in 2026.
• Per Business Quant, the three latest DFTX Other Non-Current Liabilities figures stand at $559000.0 (Q1 2026), $496000.0 (Q4 2025), and $519000.0 (Q3 2025).

Peer Comparison